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CD46-Mediated Transduction of a Species D Adenovirus
Vaccine Improves Mucosal Vaccine Efficacy
Zenaido T. Camacho,1 Mallory A. Turner,2 Michael A. Barry,3 and Eric A. Weaver3
Abstract
The high levels of preexisting immunity against Adenovirus type 5 (Ad5) have deemed Ad5 unusable for
translation as a human vaccine vector. Low seroprevalent alternative viral vectors may be less impacted by
preexisting immunity, but they may also have significantly different phenotypes from that of Ad5. In this study
we compare species D Ads (26, 28, and 48) to the species C Ad5. In vitro transduction studies show striking
differences between the species C and D viruses. Most notably, Ad26 transduced human dendritic cells much
more effectively than Ad5. In vivo imaging studies showed strikingly different transgene expression profiles.
The Ad5 virus was superior to the species D viruses in BALB/c mice when delivered intramuscularly. However,
the inverse was true when the viruses were delivered mucosally via the intranasal epithelia. Intramuscular
transduction was restored in mice that ubiquitously expressed human CD46, the primary receptor for species D
viruses. We analyzed both species C and D Ads for their ability to induce prophylactic immunity against
influenza in the CD46 transgenic mouse model. Surprisingly, the species D vaccines again failed to induce
greater levels of protective immunity as compared with the species C Ad5 when delivered intramuscularly.
However, the species D Ad vaccine vector, Ad48, induced significantly greater protection as compared with
Ad5 when delivered mucosally via the intranasal route in CD46 transgenic mice. These data shed light on the
complexities between the species and types of Ad. Our findings indicate that more research will be required to
identify the mechanisms that play a key role in the induction of protective immunity induced by species D Ad
vaccines.
Introduction
The need for improved influenza vaccines has beenrecently highlighted. With the pandemic swine flu of
2009 and the most recent early and widespread high levels of
influenza activity in the United States, people are becoming
more educated to the fact that our current influenza vaccine
program has significant limitations (Velan, 2011). Even in a
normal season, 5–15% of the world’s population is affected
by epidemics and has upper respiratory tract infections an-
nually, 3–5 million have severe illness, and 250,000–500,000
cases result in death (WHO, 2014). In the United States,
seasonal influenza affects up to 20% of the population and
results in 200,000 hospitalizations and approximately 37,000
deaths each year. The World Health Organization (WHO)
states, ‘‘Influenza rapidly spreads around the world in sea-
sonal epidemics and imposes a considerable economic bur-
den in the form of hospital and other health care costs and lost
productivity. In the United States of America, it is estimated
that influenza epidemics cost up to $167 billion per year’’
(Molinari et al., 2007). Our society is becoming less and
less trusting of our traditional influenza vaccine (Borjesson
and Enander, 2013). A vaccine technology that the major-
ity of people now know is only effective 59% of the time
(Osterholm et al., 2012). Although recent studies have shown
that high-dose influenza vaccine formulations have been
shown to improve the vaccine efficacy in the elderly and
immunocompromised, there is still a need to improve the
current vaccine technology (Falsey et al., 2009; McKittrick
et al., 2013).
Ad type 5 (Ad5) has been shown to be a very good viral
vector for use as an influenza vaccine. It has been proven to
be an effective influenza vaccine in many animal models
and against many strains of influenza, including highly
pathogenic avian influenza (HPAI) (Lo et al., 2008; Park
et al., 2009; Toro and Tang, 2009; Zhou et al., 2010).
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However, Ad5 seroprevalence is an undeniable fundamental
problem to its use as an influenza vaccine vector in humans.
There are very high levels of preexisting immunity to Ad5
in all populations (Abbink et al., 2007; Mast et al., 2010;
Barouch et al., 2011). In many populations the preexisting
immunity is 100% by the age of 2 (Abbink et al., 2007). The
failure of the HIV vaccine STEP trial emphasized the lim-
itations of using this virus as a vaccine vector (Sekaly, 2008;
McMichael and Haynes, 2012; Cohen, 2013). Our solution
is the creation of new vaccine vectors that are based on less
common types of adenovirus (Ad) and study them as viral
vectored influenza vaccines.
Ads are naked, icosahedral viruses with double-stranded
DNA genomes of *36 kb. There are approximately 60 dif-
ferent types of Ad divided into 7 species (A–G) (Wy Ip and
Qasim, 2013). Researchers, including ourselves, have begun to
look into the use of low-seroprevalent Ads as alternative viral
vectored vaccines (Abbink et al., 2007; Waddington et al.,
2008; Schuldt et al., 2012; Teigler et al., 2012; Zahn et al.,
2012; Baden et al., 2013; Weaver, 2013; Weaver and Barry,
2013). While these alternative viral vectors may have a lower
seroprevalence, the differences in their biology as compared
with Ad5 have started to come into question. It is a risky
assumption to assume that all Ads share the same phenotype
(Coughlan et al., 2012). In this study we show that there is a
significant degree of difference in phenotypes even within
the same species of Ad. Using a transgenic human CD46-
expressing mouse model, we were able to restore the intra-
muscular (i.m.) species D transduction efficiency. However,
i.m. vaccination was not improved. Vaccine efficacy was im-
proved only when the species D Ad, Ad48 in particular, was
delivered by the intranasal (i.n.) route in a human CD46
transgenic mouse model. As species D Ads are generally as-
sociated with the gastrointestinal and ocular mucosal tissues,
they may be optimal vectors for the induction of mucosal
immunity (Fields et al., 2013). These results indicate the im-
portance of evaluating these new alternative serotypes as vac-
cine vectors for potential translation into human clinical trials.
Materials and Methods
Viruses
The species C and D Ad constructs used in this study
were cloned and modified as previously described (Weaver
and Barry, 2013). The modified viral genomes were digested
from their plasmid backbones using PacI and transfected
into 293 cells. The rescued virus was amplified and purified
on two sequential CsCl gradients. Each Ad serotype was
modified to express an eGFP-luciferase (GFPLuc) fusion
protein in place of the adenoviral E3 genes in order to
make replication-competent (RC) vectors. Since replication-
defective (RD) viral vectors are considered to be safer al-
ternatives, we created an RD E1-deleted Ad28 expressing
GFPLuc (Ad28-GFPLuc) for comparison of the viral vector
platforms. RD species D Ads were rescued as previously
described with the exception that 293-E4-pIX cells (Microbix)
were used to amplify the virus. Ad28 was chosen because
it was neither the best nor the worst at transduction in vitro
and in vivo and we felt that it was a good middle repre-
sentative of the three species D Ads. This also reduced the
number of animals needed for the studies. Since there was
no significant difference in the in vivo transduction levels by
either RD or RC platform, we chose to test only RD viruses
for use as influenza vaccines. These vaccines were con-
structed by deleting the E1 genes and replacing them with a
CMV expression cassette expressing a centralized H1
hemagglutinin (HA) gene. We chose to use a centralized H1
antigen (HA1-con) since, in the case of vaccine mismatch, it
has been shown to induce broader levels of anti-influenza
immunity as compared with wild-type HA genes (Weaver
et al., 2011).
The species C Ad5 RC vector contained a CMV-GFPLuc
expression cassette in between the E1A and B genes. This
vector also had a partial E3 deletion that resulted in overex-
pression of the ADP gene as previously described (Doronin
et al., 2000). Ad5-RD was created using the Stratagene Ad-
Easy system and had a CMV expression cassette in place of
the E1 genes and had a complete E3 deletion.
Cells
Peripheral blood mononuclear cells (PBMCs) were col-
lected under a Mayo Clinic institutional review board-
approved protocol and informed consent was obtained from
all donors. PBMCs were used to generate human monocyte-
derived immature dendritic cells by the ‘‘adherence method’’
or by CD14 isolation as previously described (Gottschalk
et al., 2003; Leen et al., 2004). Adherent or CD14-selected
monocytes were then cultured in Cell Genix/GlutaMAX-I
medium with 800 U/ml granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Sargramostim Leukine; Im-
munex) and 1000 U/ml interleukin-4 (IL-4; R&D Systems)
for 5 days, with IL-4 and GM-CSF replenishment on days 2
and 4. On day 5, they were cryopreserved. A549, RAW
264.7, and Jurkat cells were obtained from ATCC. A549
cells were cultured in complete Dulbecco’s modified Eagle’s
medium (cDMEM) that contained 10% heat-inactivated fetal
calf serum (Gibco) and penicillin/streptomycin at 100 U/ml
(Gibco). RAW 264.7 and Jurkat cells were cultured in com-
plete RPMI medium (cRPMI) that contained 10% heat-
inactivated fetal calf serum and penicillin/streptomycin at
100 U/ml.
In vitro transduction
Six-well plates were seeded with cells 24 hr before infec-
tion. The cells were infected with 1 · 104 vp/cell of each
virus. Images of GFP fluorescence were collected and the
luciferase activity was determined at 24 hr postinfection using
the reporter passive lysis 5 · buffer and luciferase assay re-
agent (LAR; Promega) as described by the manufacturer
protocol. Briefly, the medium was removed and 800 ll of
DPBS was added. About 200 ll of 5 · passive lysis buffer
was added to each well and mixed. The plate was incubated
at room temperature for 5 min and 200 ll of LAR was added.
The plate was shaken on an orbital shaker and luciferase
activity was measured using a Beckman Coulter DTX 880.
Ethics statement
Female BALB/c mice (6–8 weeks old) were purchased from
Charles River Laboratories. The human CD46 + transgenic
mice were established on a C57/BL7 · C3H hybrid genetic
background and supplied by the Mayo Clinic Toxicology An-
imal Core (Mrkic et al., 1998). CD46 + transgenic mice (6–10
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weeks old) were generated under the breeding protocol IACUC
A61312. The mice were housed in the Mayo Clinic Animal
Facility under the Association for Assessment and Accredita-
tion of Laboratory Animal Care (AALAC) guidelines with
animal use protocols approved by the Mayo Clinic Animal Use
and Care Committee (protocol A64612). All animal experi-
ments were carried out according to the provisions of the An-
imal Welfare Act, PHS Animal Welfare Policy, the principles
of the NIH Guide for the Care and Use of Laboratory Animals,
and the policies and procedures of Mayo Clinic.
In vivo luciferase imaging
Mice were anesthetized by intraperitoneal (i.p.) injection
with ketamine (140 mg/kg)/xylazine (5.55 mg/kg) and were
immunized by i.m. or i.n. routes. Mice immunized by the
i.m. route received 1 · 1010 vp/mouse in two 25 ll injections
into each quadricep muscle (50 ll total volume). Mice im-
munized by the i.n. route received 1 · 1010 vp/mouse of Ad
in two 10 ll instillations into each nare (20 ll total volume).
The luciferase-expressing viruses were administered as in-
dicated and the mice were imaged 24 hr after administration
on a Lumazone Imaging System (Roper Scientific) as de-
scribed by Hofherr et al. (2008). Mice were anesthetized
with ketamine/xylazine and injected i.p. with d-luciferin at a
concentration of 20 mg/ml in PBS in a volume of 200 ll, and
the mice were immediately placed into the Lumazone and
images were captured. All images were taken with a 10 min
exposure and 4 · 4 binning. Data analysis was performed on
each image using background-subtracted sum intensities
detected by the Lumazone Imaging Software and graphed
using Prism Graphing Software.
Immunizations and influenza virus challenge
Mice were anesthetized by i.p. injection with ketamine
(140 mg/kg)/xylazine (5.55 mg/kg). Mice immunized by the
i.m. route received the specified Ad virus in two 25 ll in-
jections into each quadricep muscle (50 ll total volume).
Mice immunized by the i.n. route received the Ad vaccine in
two 10 ll instillations into each nare (20 ll total volume).
We chose to test Ad26 and 48 because they represented the
high and low levels of in vitro and in vivo transduction and
would represent the extremes of the 3 species D Ads. Ad-
ditionally, fewer animals were required for the vaccine
studies. Three weeks after immunization, the mice were
challenged i.n. with mouse-adapted influenza A/PR/8/34.
The mice were anesthetized with ketamine/xylazine as de-
scribed for animal immunizations. The anesthetized mice
were placed on their back and challenged with 100 MLD50
(50% mouse lethal doses) of influenza virus A/PR/8/34 us-
ing two 10 ll instillations into each nare (20 ll total vol-
ume). The mice were observed for morbidity and weight
loss over subsequent days and were euthanized if weight
loss reached 25% of initial body weight. Since the mean
weight loss is no longer representative once an animal is
removed from a group, weight loss data were censored when
survival dropped below 100%.
Statistical analyses
All data were analyzed using GraphPad Prism 4 software.
Statistical significance was determined using Unpaired, two-
tailed T-tests, ANOVA with Bonferroni posttest, and Log-
rank (Mantel–Cox). p-Values £ 0.05 were considered sta-
tistically significant.
Results
In vitro comparison of species C and species D Ads
While Ad5 induces a robust immune response as a vaccine
carrier, it suffers from Ad-specific preexisting immunity in
most humans. To circumvent this problem, we cloned the
genomes of three low-seroprevalent species D Ads, Ad26,
Ad28, and Ad48, and modified them to express GFPLuc in
place of E1 or E3 genes (Weaver and Barry, 2013). As an
initial test of vector functions, several cell lines were infected
with recombinant species D Ad26, Ad28, and Ad48 viruses
and compared with cells infected with a species C Ad5 virus
(Fig. 1). The species C Ad5 transduced the A549 human lung
cells at least 2-fold more efficiently than the species D Ads
(Fig. 1A and B). Ad26 was more efficient than Ad5 for in-
fection of Jurkat human T lymphocyte cells (Fig. 1A and C).
In contrast, Ad5 virus was more than 30-fold more efficient in
transducing RAW264.7 mouse monocyte/macrophages (Fig.
1A and D). Most interestingly, the species D viruses were
much more efficient at transducing human dendritic cells
in vitro (Fig. 1A and E). Of the species D viruses, Ad26
mediated 36-fold higher transduction of human dendritic cells
than Ad5 (Fig. 1E). These data suggested that the species D
Ads have different cell tropism than Ad5 and that this may
have utility when vaccinating against influenza.
In vivo transduction by Ads after i.m. injection
Mice were immunized i.m. with 1 · 1010 vp/mouse of
species D and species C Ads and luciferase expression was
imaged 24 hr later (Fig. 2). By this route, Ad26, Ad28, and
Ad48 produced significantly lower levels of luciferase activity
as compared with the Ad5 vector ( p £ 0.0002, p < 0.005, and
p < 0.0003, respectively). When RD E1-deleted Ad28-RD was
tested, it also induced significantly lower luciferase expression
than Ad5 and this expression was statistically lower than that
mediated by its RC Ad28 counterpart ( p = 0.02). In contrast,
Ad5-RD had higher luciferase expression than RC Ad5, al-
though these differences did not reach statistical significance.
In vivo transduction by Ads after i.n. administration
The Ad vectors were administered i.n. at a dose of
1 · 1010 vp/mouse to compare mucosal transgene expression
levels. Imaging at 24 hr demonstrated that the species D Ads
mediated higher luciferase expression in the nasal mucosa
than the species C Ad5 viruses (Fig. 3). In particular, Ad26
produced 3- and 7-fold higher expression than Ad5 and
Ad5-RD, respectively ( p = 0.03 and 0.01, respectively). All
species D Ad viruses induced statistically higher levels of
luciferase expression as compared with the species C Ad5-
RD virus ( p £ 0.05). Ad28 and Ad28-RD produced equiva-
lent levels of luciferase activity when delivered intranasally.
In vivo transduction in CD46 transgenic mice
Several studies indicate that CD46 is the main receptor
for species D Ad binding (Wu et al., 2004; Wang et al.,
2007; Li et al., 2012; Teigler et al., 2012). Since mice have
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limited expression of CD46 and mouse CD46 may not be
sufficiently homologous for use as a receptor, we decided to
investigate the use of CD46 transgenic mice for future
studies (Tsujimura et al., 1998). Individual mice were im-
munized intramuscularly with 1 · 1010 vp of Ad26, 28, and
48 and compared with Ad5 (Fig. 4). Because of interference,
the hair covering the quadriceps was removed by shaving.
As expected, there were no statistically significant differ-
ences in virus transduction and luciferase expression levels
of the species C and D Ads (Fig. 4). Overall, the species D
FIG. 1. Species C and D Ad tissue tropism. Species C and D viruses expressing GFPLuc were used to infect human lung
carcinoma cells (A549) (B), human T lymphocyte ( Jurkat) (C), mouse macrophages (RAW 264.7) (D), and human dendritic
cells (CD14 +) (E). Representative images are shown at 400 · magnification (A). The cells were lysed at 24 hr postinfection
using 5 · passive lysis buffer. Luciferase assay reagent was added and luminescence was measured using a Beckman
Coulter DTX 880. Luminescence values represent the luciferase activity of the entire well of a 6-well plate. Ad, adenovirus.
Color images available online at www.liebertpub.com/hum
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Ad virus transduction levels were restored to a level
equivalent to that of species C Ad5. We attempted to
evaluate the in vivo expression levels of i.n. immunized
CD46 mice. However, we were unable to reach detectable
levels. This problem can be attributed to the signal being
blocked by the dark skin and facial hair over the nasal area
(data not shown).
Protection of CD46 + mice by systemic
i.m. immunization
In order to determine if the restoration of i.m. transduc-
tion by species D Ads in CD46 + mice would improve
vaccine efficacy, we immunized CD46 + transgenic mice i.m.
with serial dilutions of Ad26-RD, Ad48-RD, and Ad5-RD
viruses expressing the centralized hemagglutinin (HA1-con).
The mice were challenged i.n. 3 weeks postimmunization with
100 MLD50 of mouse-adapted influenza A/PR/8/34. Un-
fortunately, restoring the transduction levels of the species D
Ad viruses did not result in the restoration of vaccine effi-
cacy, at least not by the i.m. route. Weight loss, disease, and
death was observed in all mice immunized with Ad26-RD
and Ad48-RD vaccines (Fig. 5A and B). However, the
species C Ad5-RD vaccine was capable of protecting mice
from severe disease at all doses (Fig. 5C). In the case of i.m.
immunization in CD46 mice, the species D Ad5-RD was a
superior vaccine as compared with the species D Ads 26-RD
and Ad48-RD.
Protection of CD46 + mice by mucosal
i.n. immunization
Previous studies have shown that species D Ads could
induce protective anti-influenza immunity in BALB/c mice
when immunized intranasally (Weaver and Barry, 2013).
While we were unable to obtain in vivo imaging of i.n. mice,
our i.m. data indicate that species D Ad transduction is re-
stored in the CD46 + transgenic mice. Since CD46 ex-
pression is constitutive and ubiquitous in our mouse model,
we can only assume that transduction via the CD46 receptor
is also occurring in the intranasally immunized mice. In vivo
transduction data indicate that species D Ads are trans-
ducing BALB/c mice via an alternative receptor (Fig. 3)
(Weaver and Barry, 2013). Here we determine if the resto-
ration of the CD46 receptor would result in a synergistic
improvement of vaccine efficacy in i.n. immunized mice.
We immunized groups of CD46 + mice intranasally with
serial dilutions of Ad26-RD, Ad48-RD, and Ad5-RD vac-
cines. The mice were then challenged 3 weeks after im-
munization with 100 MLD50 of mouse-adapted influenza
A/PR/8/34. Based on previous studies, the species D Ad
vaccines were better at protecting mice when delivered i.n.
as compared with i.m. (Weaver and Barry, 2013). As ex-
pected, both Ad26-RD and Ad48-RD induced greater levels
of protection when delivered intranasally. Ad26-RD and
Ad5-RD vaccines induced similar levels of protection against
the influenza virus challenge (Fig. 6A and C). However, the
FIG. 2. In vivo analysis of
transgene expression and
biodistribution by species C
and D Ad vectors by systemic
immunization. Groups of four
BALB/c mice were adminis-
tered 1 · 1010 viral particles
of the indicated vectors in-
tramuscularly. Twenty-four
hours later the animals were
anesthetized, injected with
luciferin, and imaged for lu-
ciferase activity. All images
were taken with a 10 min ex-
posure and 4 · 4 binning.
Color images available online
at www.liebertpub.com/hum
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Ad48-RD vaccine induced the greatest level of protection
and was the only vaccine to induce 100% survival at a dose
of 1 · 108 vp (Fig. 6B). Interestingly, Ad48-RD delivered i.n.
was as good at inducing protective immunity as Ad5-RD
delivered intramuscularly. This is in contrast to Ad5-RD,
where the greatest levels of protection are induced by i.m.
immunization.
Discussion
As an alternative to the highly seroprevalent species C
Ad5 vector, we have characterized three human species D
Ad vaccine vectors. An initial characterization of cell tro-
pism showed that species D viruses had lower levels of
luciferase expression in human lung epithelial cells as
compared with the species C Ad5. This could be explained
by the fact that Ad5 is a respiratory pathogen and is able to
replicate efficiently in human lung A549 cells, whereas
Ad26, Ad28, and Ad48 were all isolated from rectal swabs
from a 9-month-old male, 30-month-old male, and an im-
munocompromised adult, respectively (Hierholzer et al.,
1991; Schnurr and Dondero, 1993). Both species C and D
viruses were capable of infecting human T lymphocytes;
however, there was a high degree of variation in the species
D viruses. Again, this emphasizes the differences in Ad
phenotypes, even within the same species. Species C viruses
were also much more capable of infecting macrophages as
compared with all of the species D viruses. This observation
has been observed in other studies in which Ad was used to
eliminate Kupffer cells that ultimately allowed for greater
transgene expression (Shashkova et al., 2008; Khare et al.,
2011). Most interestingly, the species D Ads were much
more capable of transducing the professional antigen pre-
senting human dendritic cells. Again, we see a high level of
variation in the 3 species D Ads; however, the lowest level
of Ad48 is still > 2-fold higher than the species C Ad5.
The primary receptor for Ad5 virus entry is the coxsackie
and Ad receptor (CAR). Unfortunately, CAR is sequestered
to the basolateral membrane of the mucosal epithelia,
making Ad5 less effective at transducing the nasal and lung
epithelial cells (Grubb et al., 1994; Zabner et al., 1997). In
addition, CAR is not expressed on dendritic cells, making
them refractory to Ad5 transduction (Mercier et al., 2004).
Previous studies by our group have modified Ad5 to express
a chimeric fiber protein that utilizes the reovirus sigma
protein for transduction into dendritic cells via the junc-
tional adhesion molecule 1 ( JAM1) as the primary receptor
(Mercier et al., 2004). While these modified viruses show
lower levels of transduction by the i.n. route, they induced
equivalent T cell immunity (Weaver et al., 2012). The pri-
mary receptor for species D Ads is CD46, which is ex-
pressed on all human nucleated cells, including dendritic
cells, and therefore more readily transduced (Ni et al.,
2005). This is of interest since dendritic cells play a key role
FIG. 3. In vivo analysis of
transgene expression and
biodistribution by species C
and D Ad vectors by mucosal
immunization. Groups of
four BALB/c mice were ad-
ministered 1 · 1010 viral par-
ticles of the indicated vectors
intranasally. Twenty-four
hours later the animals were
anesthetized, injected with
luciferin, and imaged for lu-
ciferase activity. All images
were taken with a 10 min
exposure and 4 · 4 binning.
Color images available on-
line at www.liebertpub.com/
hum
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in the development and maintenance of immune responses
and a vaccine vector that is capable of transducing these
cells may be a more effective vaccine.
When we looked at the in vivo tropism of the viral vec-
tors, we found that the species C Ad5 virus was much more
capable of transducing muscle in BALB/c mice. The species
C Ad5 virus had statistically higher levels of transgene ex-
pression levels as compared with all of the species D viru-
ses. This was a disappointing discovery, but not unexpected
when we consider the differences in cell tropism observed
in vitro. In contrast, when the viruses were delivered to
BALB/c mice mucosally by i.n. immunization, we found the
opposite result. In this case, the species D Ad viruses had
significantly higher transgene expression level than the
species C viruses. An interesting note was the inversion of
transgene expression by the RC and RD versions of the
viruses. In the case of i.m. immunization, Ad5-RD was
greater than Ad5, whereas Ad28 was greater than Ad28-RD.
The opposite was observed when the viruses were deliv-
ered mucosally by i.n. immunization. Mucosally, Ad5 was
greater than Ad5-RD, whereas Ad28 and Ad28-RD were
almost equivalent. Even though these differences are mod-
est, they may still be important. This indicates that the RD
form of the species D Ad is equivalent to the RC form. This
is important since the defective form has a limited capacity
to express viral proteins without the E1 gene. Therefore, the
defective form is a safer vaccine platform while at the same
time remaining as potent as an RC form. Of note, we found
that the species C Ad5 intranasally immunized mice had a
small amount of detectable luciferase expression in the
lower respiratory tract, whereas no luciferase signal was
detected in the lower respiratory tract of species D Ad im-
munized mice (Fig. 3). We hypothesize that since mouse
macrophages are more susceptible to Ad5 virus it may be
that this expression is because of alveolar macrophage
transduction. Additionally, species C Ads cause human re-
spiratory disease and may be more apt to induce disease in a
broader range of lung tissue in mice as compared with
species D Ads.
In general, BALB/c mice do not express CD46, the pri-
mary receptor for species D Ads (Wu et al., 2004). Mice
express CD46 only in the testis, and mouse and human
CD46 are *50% divergent at the amino acid level (Inoue
et al., 2003). Our data clearly show species D Ad trans-
duction of mouse mucosal tissue and luciferase expression
in vivo. Therefore, either mouse CD46 is also expressed in
the mucosal epithelium or the species D viruses are trans-
ducing through a secondary receptor. One explanation for
the high levels of species D Ad transduction in the nasal
mucosa of the BALB/c mice is that some studies have
suggested sialic acid as an alternative receptor (Arnberg
et al., 2000a,b, 2002). The use of transgenic mice expressing
human CD46 allowed us to explore the use of the vaccines
in the context of the primary receptor. We were able to
FIG. 4. Restoration of spe-
cies D Ad transduction in
CD46 transgenic mice. Groups
of five human CD46 + trans-
genic mice were administered
1 · 1010 viral particles of the
indicated vectors intramuscu-
larly. Twenty-four hours later
the animals were anesthetized,
injected with luciferin, and
imaged for luciferase activity.
All images were taken with a
10 min exposure and 4 · 4
binning. Color images avail-
able online at www.liebertpub
.com/hum
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restore the i.m. transduction of the species D Ads to a level
equal to the Ad5 virus. We assumed that this restoration of
transgene expression would lead to increased levels of
vaccine efficacy. However, we were surprised to find out
that the species D vaccines were no better when delivered
i.m. regardless of the presence of human CD46. We can
only speculate as to why the vaccine efficacy was not re-
stored in the i.m. immunized CD46 transgenic mice. Since
human CD46 is a complement regulatory protein that
functions to control innate immune responses, it may also
act to quench the vaccine-induced immunity (Oglesby et al.,
1992; Hartman et al., 2008). Perhaps while serving as the
primary receptors for species D Ads, CD46 may also induce
immune dysfunction in the vaccinated mice as indicated by
the lack of improved vaccine efficacy. The Ad5 vaccine
does not interact with CD46 and there was no difference in
vaccine efficacy in either BALB/c or CD46 transgenic mice
(BALB/c data not shown). When mice were immunized
mucosally by the i.n. route, we did see an improvement of
vaccine efficacy by the species D vaccine but not the Ad5
species C vaccine. Again, the availability of a secondary
receptor as well as the primary CD46 receptor may explain
this difference. In addition, there may be different im-
mune responses to the vaccine in the mucosal compartment.
It is very possible that the interaction between the Ad vac-
cine and CD46 in the systemic and mucosal immune
FIG. 5. Systemic intramuscular immunization weight loss and survival. The vaccine efficacy of Ad26 (A), Ad48 (B), and
Ad5 (C) vaccines on weight loss, disease, and death in intramuscularly immunized human CD46 + transgenic mice was
determined by vaccinating with serial dilutions of Ad-vectored viruses (1 · 109 to 1 · 107 vp/mouse). Three weeks post-
vaccination the mice were challenged intranasally with 100 MLD50 of mouse-adapted influenza virus A/PR/8/34. The mice
were monitored for weight loss and disease. Mice that lost ‡ 25% of their body weight were removed from the study and
humanely euthanized. Color images available online at www.liebertpub.com/hum
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compartments results in significantly different vaccine-in-
duced immune responses. Future studies that investigate this
interaction may reveal the mechanisms for the regulation of
adaptive immunity in these two different compartments.
A previous study that investigated the use of low-
seroprevalent Ads as vaccines for influenza also showed
enhanced vaccine efficacy by the mucosal route in BALB/c
mice (Weaver and Barry, 2013). In the absence of CD46 it
was shown that species D Ad vaccines were equally effec-
tive at inducing anti-influenza immunity when the vaccines
were delivered mucosally. The previous studies were per-
formed using E3-deleted RC species D Ad vaccines,
whereas this study used E1-deleted RD vaccines. It is pos-
sible that since the RC vaccines do not possess the immu-
noevasive E3 genes they are more immunogenic or it could
be that transcription of viral genes is also playing a role in
the induced immune responses. Although there are many
possibilities to explain the observed differences in vaccine
efficacy, only future studies on the viral vaccine and host
interactions will elucidate these mechanisms. Hopefully,
these studies will shed light on and improve our ability to
drive antipathogen immune responses.
FIG. 6. Mucosal intranasal immunization weight loss and survival. The vaccine efficacy of Ad26 (A), Ad48 (B), and Ad5
(C) vaccines on weight loss, disease, and death in the intranasally immunized in human CD46 + transgenic mice was
determined by vaccinating with serial dilutions of Ad-vectored viruses (1 · 109 to 1 · 107 vp/mouse). Three weeks post-
vaccination the mice were challenged intranasally with 100 MLD50 of mouse-adapted influenza virus A/PR/8/34. The mice
were monitored for weight loss and disease. Mice that lost ‡ 25% of their body weight were removed from the study and
humanely euthanized. Color images available online at www.liebertpub.com/hum
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